Science1 publisher3 min readPublished
Physician practice roll-ups have collapsed to 105 deals, and state review laws are the suspect
PitchBook counts 105 physician practice management deals in the first half of 2026, against 851 in all of 2021. More than a dozen states now screen health care acquisitions.
The Scientist · Science desk
Drafted by a language model from the sources cited here and checked against its claim ledger before publication. How we use AISend a correction
What happened
- Investments in physician practice management businesses, which run clinics' billing and operations, have fallen from a high of 851 deals in 2021 to 105 deals in the first half of 2026, according to new data from PitchBook.
- Over a dozen states now have laws enhancing their oversight of private equity deals in health care.
- A new report says the expanded state oversight is putting a crimp in health care dealmaking, and STAT frames the finding as state laws that may be curbing private equity takeovers of physician groups.
- If second-half 2026 deal volume matches the first half, full-year 2026 would total about 210 deals, roughly 25 percent of the 851 recorded in 2021, a decline of about 75 percent.
- Physician practice management is on track to see about half the number of deals in 2026 as it did in 2025.
Compiled by The ScientistSomething wrong?How this is made
Why it matters
Private equity dealmaking in physician practice management has fallen to 105 transactions in the first half of 2026, down from a 2021 peak of 851, according to new PitchBook data reported by STAT [1]. The proximate suspect is regulatory: more than a dozen states now have laws expanding their oversight of private equity deals in health care, and a new report says that oversight is constraining dealmaking [2][3].
The size of the drop matters more than its direction. If the second half of 2026 matches the first, the year closes near 210 deals, roughly a quarter of the 2021 total [4]. That is consistent with the report's own framing, which has the sector on track for about half as many deals in 2026 as in 2025 [5]; taken together, those two figures imply something on the order of 420 deals in 2025, so the contraction is not a single bad year but a second consecutive halving [6]. "It's certainly been a big decrease," Paul Pitts, a partner at Reed Smith who works with health care providers, told STAT [7].
Two cautions before anyone builds a model on this. First, 105 is a half-year number and 851 is a full-year number, so the headline comparison overstates the gap unless you annualise [1][4]. Second, the causal claim is soft: the source says state laws may be curbing takeovers, and interest rates, exit backlogs, and reimbursement pressure all sit in the same period without being separated out in what was published [2][3]. Correlation with a wave of statutes is not proof that the statutes did the work.
The operational consequence stands regardless of how the causation splits. Practice management companies are the entities that run clinics' billing and operations [1], and the standard growth plan in that business has been serial acquisition. A plan built that way now has a second failure mode alongside financing. A deal can be fully funded, priced, and papered and still sit in a state review queue, and in more than a dozen states there is now a body with standing to look at it [2]. Timelines lengthen, and the value of a signed letter of intent decays.
For operators, the practical work is unglamorous. Know which states in your footprint have enacted review regimes and what triggers them [2]. Assume a diligence and notice period that is not in your current base case. Price organic growth, contract restructuring, and same-site productivity as though acquisitions may not close, because at a sector-wide run rate near a quarter of the 2021 level, the average acquirer is already living in that world [4].
Watch whether the second half of 2026 confirms the 210-deal run rate or the first half proves to have been the trough [4]. Watch whether the count of states with enhanced oversight keeps climbing past a dozen [2]. And watch for data that separates regulatory drag from the cost of capital, which the published material does not do [3].